Brain imaging may expose a shared marker in PTSD and alcohol addiction
NCT ID NCT06371404
First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time
Summary
Researchers at Yale University are using PET brain imaging with a radiotracer called Bavarostat to measure levels of an epigenetic marker, HDAC6, in people with PTSD, alcohol use disorder, or both. The study includes 150 adults aged 18 to 70 and compares them with control groups. The goal is to see whether HDAC6 levels relate to symptoms and could guide future treatment development.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Bavarostat, a radiotracer for PET brain imaging that binds to the epigenetic marker HDAC6
- What this could lead to
- If this works, it could reveal a brain marker linked to PTSD and alcohol use disorder, pointing toward new treatments that target HDAC6.
- What could go wrong
- This is an early imaging study, not a treatment trial. It may not find clear differences, and any link to symptoms might not lead to effective therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Up to 150 adult male and female subjects, aged 18-70, who are in general good health, meet the inclusion criteria, and who do not meet any of the exclusion criteria will be eligible for enrollment into Aim 1, Aim 2, or Aim 3 of the study. Up to 30 PTSD and 30 TC subjects will be enrolled into Aim 1 of the study. Up to 30 AUD and 30 HC subjects will be enrolled into Aim 2 of the study. Up to 30 comorbid PTSD \& AUD subjectswill be enrolled into Aim 3 of the study.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Willing and able to give voluntary written informed consent 2. Is able to read and write, able to communicate effectively with the investigator, and comply with all study requirements, restrictions, and directions of the research staff 3. Men or women, aged 18 to 70, at screening 4. In good general health as evidenced by medical history, physical examination, ECG, serum/urine biochemistry, hematology, and serology tests 5. Participants with PTSD will have a current diagnosis of PTSD according to DSM-5 criteria (CAPS-5 ascertained diagnosis, confirmed by the Principal Investigators. TC subjects must have a DSM-5 criteria traumatic event with no PTSD diagnosis 6. Participants with AUD will have a current diagnosis of AUD according to DSM-5 criteria (i.e., SCID-5 ascertained diagnosis, confirmed by the Principal Investigators); 7. Participants with AUD will meet the following drinking criteria: males will drink \> 14 drinks per week and exceed 4 drinks per day at least twice per week; females will drink \> 7 drinks per week and exceed 3 drinks per day at least twice per week. They must meet drinking criteria during a consecutive 30-day period within the 90 days prior to intake. 8. Healthy subjects will have no current or past diagnosis of AUD or other significant substance use disorder. They will drink less than 5 alcoholic drinks per week with no heavy drinking days (i.e., \>4 drinks/day for men; \>3 drinks/day for women) in the last 30 days; Exclusion Criteria: 1. Current significant medical condition such as neurological, cardiovascular, endocrine, renal, liver, or thyroid pathology that would impact the integrity of the data (note that elevated liver enzymes for individuals with AUD will not be exclusionary) 2. Past or current neurological disorder or disorders affecting the brain including but not limited to multiple sclerosis, history of stroke, brain tumors, traumatic brain injury with loss of consciousness, seizure disorder; 3. Current significant psychiatric disorder including severe substance use disorder (other than alcohol or tobacco use disorders\*), and past or current psychotic symptoms, 4. Regular use in the past 6 months of any prescription, psychoactive or herbal medications (e.g., antidepressants, antipsychotics, anxiolytics) that would impact the integrity of the data (e.g., naltrexone); No subject will be asked to stop taking medication to participate in the study; 5. Pregnancy or lactation 6. Blood donation within eight weeks of the start of the study. 7. History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto). 8. Unable to safely discontinue or hold aspirin and other NSAID use 9. MRI incompatible implants (i.e., such as pacemaker, artificial joints, non-removable body piercings) and other contraindications for MRI, such as claustrophobia, having implanted or embedded metal objects/fragments or fragments in the head or body that would present a risk during the MRI scanning procedure, or have worked with ferrous metals either as a vocation or hobby (for example, as a sheet metal worker, welder, or machinist). 10. Participation in other research studies involving inonizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits for healthy volunteers. 11. Subject who has current, past, or anticipated exposure to radiation in the work place within one year of the proposed research scans that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits. 12. Has any condition that, in the opinion of the investigator, would prevent compliance with the study protocol. 13. History of complicated alcohol withdrawal including history of delirium tremens; seizure, hospitalization for withdrawal. 14. Alcohol intoxication at time of screening. 15. A CIWA score ≥8 at intake or on scan day. 16. Subjects who are, in the opinion of the study physician, unable to safely abstain from alcohol overnight prior to their study visits.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06518, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Investigating the Mu:Kappa opioid receptor imbalance in alcohol use disorder
- Identification of cellular and molecular mechanisms involved in the pathophysiology of alcohol use disorder by examination of cerebrospinal fluid
- Intravenous acetate as an adjunctive treatment for alcohol withdrawal in hospitalized patients
- Can a gentle brain current quiet alcohol cravings?
- Can talk therapies quiet the trauma of violence?
- Can tailored brain stimulation quiet anxiety that drugs Can't?